Get the Stockscreener App
14.68
1.73%
0.25
After Hours:
14.56
-0.12
-0.82%
Hutchmed China Limited Adr stock is traded at $14.68, with a volume of 59,227.
It is up +1.73% in the last 24 hours and down -6.79% over the past month.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
See More
Previous Close:
$14.43
Open:
$14.58
24h Volume:
59,227
Relative Volume:
1.20
Market Cap:
$2.56B
Revenue:
$603.63M
Net Income/Loss:
$468.71M
P/E Ratio:
5.4735
EPS:
2.682
Net Cash Flow:
$-59.92M
1W Performance:
-0.54%
1M Performance:
-6.79%
6M Performance:
-1.14%
1Y Performance:
-18.44%
1-Day Range:
$14.53
$14.82
1-Week Range:
$14.40
$14.99
52-Week Range:
$11.51
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.68 | 2.48B | 603.63M | 468.71M | -59.92M | 2.682 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-13-25 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
| May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-03-21 | Initiated | Jefferies | Buy |
| Oct-02-20 | Initiated | Deutsche Bank | Buy |
| Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-20 | Initiated | Goldman | Buy |
| Nov-19-19 | Initiated | CLSA | Buy |
| Oct-23-19 | Reiterated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
View All
Hutchmed China Limited Adr Stock (HCM) Latest News
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
International companies to host live webcasts at Deutsche - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - GlobeNewswire Inc.
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Vanguard Personalized Indexing Management LLC Grows Holdings in Sandstorm Gold Ltd $SAND - Defense World
Hutchmed upbeat on preclinical data for novel cancer therapy - Sharecast.com
RCSHutchmed China LtdHUTCHMED Presents Data at AACR NCI EORTC - TradingView
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
HUTCHMED Highlights HMPL-A251 Data Presented at the - GlobeNewswire
Allianz Asset Management GmbH Sells 80,000 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM - MarketBeat
Will Can Fite Biopharma Ltd Sponsored ADR stock benefit from mergersQuarterly Risk Review & Risk Controlled Stock Alerts - Trung tâm Dự báo KTTV quốc gia
Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Why HUTCHMED (China) Limited (Common Stock) (H7T1) stock is favored by hedge fundsTrade Exit Report & Technical Entry and Exit Alerts - newser.com
Will HUTCHMED (China) Limited (Common Stock) (H7T1) stock deliver stable dividendsPortfolio Update Report & Verified Chart Pattern Signals - newser.com
BOCOMI: Trump's Additional Tariffs on Imported Innovative Drugs May Have Limited Actual Impact on CN Pharmas - AASTOCKS.com
HUTCHMED (NASDAQ:HCM) Shares Gap DownTime to Sell? - MarketBeat
M Stanley: Increased Recognition Pushes Biotech Stocks to Outpace Mkt - AASTOCKS.com
Best Momentum Stock to Buy for August 19th - MSN
National Research Corporation $NRC Shares Sold by Goldman Sachs Group Inc. - Defense World
HUTCHMED (China) Limited Sponsored ADR $HCM Stock Position Raised by Goldman Sachs Group Inc. - Defense World
HUTCHMED (NASDAQ:HCM) Shares Gap UpHere's What Happened - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap Up – Should You Buy? - Defense World
Price action breakdown for HUTCHMED (China) Limited Depositary Receipt2025 Dividend Review & Risk Managed Investment Strategies - newser.com
Top Blockchain Stocks To Follow Now – September 12th - Defense World
HSBC Research Positive on LT Growth of CN Biotech, Favors INNOVENT BIO/ HANSOH PHARMA - AASTOCKS.com
G Sachs Gives ST Risk Analysis for 3 Types of Firms as US Reportedly Planning to Tighten Scrutiny on CN Innovative Drugs Could Pose 'Headline Risks' for CN Pharmas - AASTOCKS.com
CN SASAC Advocates to Accelerate Development of Central SOEs in the Biopharmaceutical Industry, Build National Team in Such Field - AASTOCKS.com
Intraday pattern recognizer results for HUTCHMED (China) Limited Depositary Receipt2025 Biggest Moves & Trade Opportunity Analysis Reports - Newser
Combining machine learning predictions for HUTCHMED (China) Limited Depositary ReceiptQuarterly Market Review & Verified Entry Point Signals - Newser
How moving averages guide HUTCHMED (China) Limited Depositary Receipt trading2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
Solventum Corporation $SOLV Shares Sold by Russell Investments Group Ltd. - Defense World
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China - GlobeNewswire
Best Momentum Stock To Buy For August 19th - Barchart.com
How to build a custom watchlist for HUTCHMED (China) Limited Depositary Receipt2025 Price Action Summary & Verified Momentum Stock Ideas - Newser
BOCOMI Lowers HUTCHMED's TP to HKD37.6; Rating Kept Buy - AASTOCKS.com
Will HUTCHMED (China) Limited Depositary Receipt bounce back from current supportFree Oversold Recovery Opportunity Stocks - Newser
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zymeworks (ZYME), HUTCHMED (HCM) and Zai Lab (ZLAB) - The Globe and Mail
Trend analysis for HUTCHMED (China) Limited Depositary Receipt this weekStock Holding Strategy Long-Term Summary Sheet - Newser
Carvana Co. (NYSE:CVNA) Major Shareholder Sells $35,236,000.00 in Stock - Defense World
Crossmark Global Holdings Inc. Sells 414 Shares of Morningstar, Inc. (NASDAQ:MORN) - Defense World
6,121 Shares in John Hancock Multifactor Large Cap ETF (NYSEARCA:JHML) Bought by Crossmark Global Holdings Inc. - Defense World
Concurrent Investment Advisors LLC Acquires New Holdings in ADMA Biologics Inc (NASDAQ:ADMA) - Defense World
Crossmark Global Holdings Inc. Has $356,000 Holdings in Nordson Corporation (NASDAQ:NDSN) - Defense World
Buenaventura Mining (NYSE:BVN) vs. Hochschild Mining (OTCMKTS:HCHDF) Head-To-Head Review - Defense World
Coinbase Global, Inc. (NASDAQ:COIN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
HUTCHMED Gains China Approval for Innovative Lung Cancer Treatment - TipRanks
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewswire
HUTCHMED (NASDAQ:HCM) Rating Increased to Strong-Buy at Wall Street Zen - Defense World
Hutchmed China Limited Adr Stock (HCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):